--- a
+++ b/clusters/9knumclustersv2/clust_103.txt
@@ -0,0 +1,57 @@
+Subject has failed or intolerant to radiotherapy.
+Subjects has failed or intolerant to temozolomide therapy.
+Participants must have received, and then progressed, relapsed, or been intolerant to, at least  standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies
+Participants must have received and then progressed or been intolerant to at least  standard treatment regimen in the advanced or metastatic setting if such a therapy exists
+Patient intolerant to imatinib
+Participants must have received, and then progressed, relapsed, or been intolerant to, at least  standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies
+Progressed on or intolerant of at least  prior cancer therapy regimens administered for metastatic disease.
+Participants must have received, and then progressed, relapsed, or been intolerant to, all standard treatment regimens with proven survival benefit in the advanced or metastatic setting according to tumor type, if such a therapy exists
+If Her positive, must have received and have progressed or are intolerant to treatment with trastuzumab for metastatic or recurrent disease
+Patients must have received and progressed through or become intolerant to fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab; if RAS wild type, patients should have received and progressed or become intolerant to the above as well as cetuximab or panitumumab containing therapies; prior therapy with regorafenib and/or TAS  is allowed
+Participants must have received, and then progressed or been intolerant to, at least  standard treatment regimen
+Patients with a known ROS--rearrangement must have progressed or been intolerant to treatment with crizotinib or entrectinib
+Patients must have progressed on, been intolerant of or refused prior oxaliplatin- and irinotecan-containing, fluorouracil-based, chemotherapeutic regimen and have disease that is not amenable to potentially curative resection; patients who have a known KRAS wild type tumor must have progressed, been intolerant of or refused cetuximab or panitumumab-based chemotherapy
+Must have progressed on at least one line of prior therapy for metastatic disease, or be intolerant to that therapy if they have not progressed, and for HER+ disease should have received prior trastuzumab
+Diagnosis of O-AML that is refractory to or intolerant to standard therapy and is no longer likely to respond to such therapy (at least one line of therapy); or Diagnosis of MDS/CMML that is refractory to or intolerant to standard therapy and is no longer likely to respond to such therapy (at least one line of therapy)
+Must be refractory or intolerant to standard lines of therapy
+Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation; HCC patients must have progressed on, been intolerant to, or refused prior sorafenib therapy; patients with BTC must have received, been intolerant of or refused at least one line of chemotherapy
+Have had disease progression, be refractory or intolerant to no more than  prior systemic regimens.
+Progressed, or been intolerant to, at least one standard treatment regimen, except for subjects in st line cohorts.
+PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nHistologically or cytologically confirmed advanced colorectal cancer; patients must have progressed on, been intolerant of or refused prior oxaliplatin- and irinotecan-containing chemotherapeutic regimen, and have disease that is not amenable to potentially curative resection; patients who have a known KRAS (or NRAS or BRAF) wild type tumor must have progressed, been intolerant of or refused cetuximab or panitumumab-based chemotherapy
+Progressive disease after failure of or intolerant to all available standard systemic treatments that have shown a documented benefit in overall survival for their respective tumor type.
+Subjects who have progressed after or were intolerant to no more than  previous systemic therapies for unresectable HCC, or are nave to systemic therapy.
+Non-MF/SS patients who are candidates for topical therapy must be refractory or intolerant to at least  prior topical therapy
+Patients intolerant or unable to receive these agents will be considered eligible.
+Must have received or been intolerant to standard therapy.
+Pathologically confirmed diagnosis of MDS by World Health Organization (WHO) criteria (including secondary and therapy-related disease) who have failed standard therapy, who are intolerant of prior therapy, or who refuse standard therapy; any prior therapy, including ibrutinib and/or lenalidomide (unless intolerant of one or both of these medications), is permitted\r\n* Hypomethylating agent failure is defined as disease progression or stable disease as best response to an adequate course of treatment (at least four cycles) with an injectable hypomethylating agent (azacitidine or decitabine)
+Participant may be either previously untreated for KS or refractory to or intolerant of any one or more prior KS therapies
+ARM A: Histologically or cytologically confirmed hepatocellular carcinoma that is refractory (by Response Evaluation Criteria in Solid Tumors [RECIST] or modified [m]RECIST criteria or with unequivocal clinical progression of disease) to or intolerant (defined as inability to administer further sorafenib due to drug related toxicities) of sorafenib based therapy or advanced solid tumor with liver predominant disease burden that has progressed on or is intolerant to standard
+All treatment regimens must have been administered for ? cycles unless patient is immediately allergic or intolerant to the regimen
+Must have progressed on, refused, or were intolerant of sorafenib.
+Intolerant of ibrutinib
+Refractory to or intolerant of standard therapy
+Has progressed after prior therapy and there is no further effective standard anticancer therapy available (including subject refuses or is intolerant)
+All patients with gastroenteropancreatic NETs must have progressed on (or are intolerant of) prior somatostatin analog
+Patients with pancreatic NETs must have progressed on (or are intolerant of) either everolimus or sunitinib
+Must have progressed on, been intolerant to, or refused gemcitabine-based therapy
+Must have received and have progressed, are refractory, or are intolerant to standard therapy appropriate for the specific tumor type. Subjects should not have received more than  prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies
+Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation; for Cohorts A and D patients must have progressed on, been intolerant to, or refused prior sorafenib therapy; Cohort E patients must have received at least one line of chemotherapy for BTC
+Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
+Resistant to or intolerant of hydroxyurea, that is, fulfilling at least  of the following criteria:
+Progression on or following, or intolerant of, at least one prior line of standard systemic therapy for advanced or metastatic gastric or pancreatic cancers.
+Progression on or following, or intolerant of, at least two prior lines of standard systemic therapy for advanced or metastatic colorectal cancers.
+CP-CML who prove resistant or intolerant to imatinib (Cohort )
+Progressed or intolerant to at least  approved prior anticancer regimen.
+Lead-in cohort: resistant or intolerant to  or more Janus kinase inhibitors (licensed or experimental).
+Randomized cohort: resistant or intolerant to prior ruxolitinib therapy. Documentation by the Investigator that the patient has exhausted available treatment options (eg, resistant or intolerant to hydroxyurea, etc).
+Patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the LABC/MBC setting
+Patients in first relapse must be chemoresistant or intolerant to chemotherapy
+Patient must have failed (progressed on or been intolerant of) prior treatment with cabozantinib or vandetanib
+Subjects must have confirmed advanced solid tumor and have progressed, are refractory, or are intolerant to standard therapy appropriate for tumor type. Subjects should not have received more than  prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies.
+Progressed following at least  line of prior therapy and there is no further approved therapy available that has been demonstrated to prolong survival (including subjects who are intolerant to the approved therapy)
+patient is intolerant of standard therapy
+Patients must have progressed on or been intolerant of prior oxaliplatin and irinotecan-containing chemotherapeutic regimen and have disease that is not amenable to potentially curative resection; patients who have a known Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type tumor must have progressed or been intolerant to cetuximab or panitumumab-based chemotherapy
+Progression of disease after at least one prior standard of care regimen or intolerant to irinotecan based regimens
+OR intolerant to second generation TKI and intolerant or refractory to imatinib mesylate
+Progressed, or been intolerant to, at least one standard treatment regimen
+Progressive disease following or intolerant of or refuses standard of care systemic therapy